Market Place
Sourcing Support
Bionomics Provide Re-domiciliation Update via Scheme of Arrangement
08 Nov 2024 //
GLOBENEWSWIRE
Bionomics to Present at 2024 CNS Summit
07 Nov 2024 //
GLOBENEWSWIRE
Bionomics Receives AUS$1M Milestone for BNC101 from Carina
04 Nov 2024 //
GLOBENEWSWIRE
Bionomics to Present at the ThinkEquity Conference
23 Oct 2024 //
GLOBENEWSWIRE
Bionomics To Participate In Maxim Healthcare Virtual Summit
14 Oct 2024 //
GLOBENEWSWIRE
Bionomics Issues Shareholder Letter On Achievements & Vision
07 Oct 2024 //
GLOBENEWSWIRE
Bionomics Limited announces intention to re-domicile to the US
01 Oct 2024 //
GLOBENEWSWIRE
Bionomics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Bionomics Announces Successful FDA End-Of-Phase 2 Meeting For BNC210
31 Jul 2024 //
GLOBENEWSWIRE
Bionomics To Discuss BNC210 Phase 2 Results For PTSD On July 31, 2024
29 Jul 2024 //
GLOBENEWSWIRE
Bionomics Starts Phase 3 Trial Of BNC210 For Social Anxiety Disorder
18 Jul 2024 //
GLOBENEWSWIRE
Bionomics Limited Announces Private Placement of up to $70.0 Million
31 May 2024 //
GLOBENEWSWIRE
Bionomics To Present At ASCP 2024 Annual Meeting
20 May 2024 //
GLOBENEWSWIRE
Bionomics Reports Results of the Full Dataset from ATTUNE Ph 2b Trial of BNC210
21 Mar 2024 //
GLOBENEWSWIRE
Bionomics to Present at the 2024 BIO CEO & Investor Conference
22 Feb 2024 //
GLOBENEWSWIRE
Bionomics Provides a Review of 2023 and of 2024 Plans
22 Jan 2024 //
GLOBENEWSWIRE
Bionomics to Present at Biotech Showcase„¢ 2024
05 Jan 2024 //
GLOBENEWSWIRE
Bionomics Presents Data on Validity of the Subjective Units of Distress Scale
06 Dec 2023 //
GLOBENEWSWIRE
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA
16 Oct 2023 //
GLOBENEWSWIRE
Bionomics` midphase PTSD clinical trial hits primary endpoint
29 Sep 2023 //
FIERCE BIOTECH
Bionomics Announces Results from Phase 2b ATTUNE Trial of BNC210
28 Sep 2023 //
GLOBENEWSWIRE
Bionomics Announces Update on the ?7 nAChR PAM Collaboration with MSD
14 Sep 2023 //
GLOBENEWSWIRE
Bionomics Completes Last Patient Last Visit in Phase 2b ATTUNE Study for PTSD
23 Aug 2023 //
GLOBENEWSWIRE
Quarterly Activities and Cashflow Report
31 Jul 2023 //
GLOBENEWSWIRE
Bionomics Announces Intention to Delist from the ASX
25 Jul 2023 //
GLOBENEWSWIRE
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation
03 Jul 2023 //
GLOBENEWSWIRE
Bionomics to Present at Upcog June Investor Conferences
15 Jun 2023 //
GLOBENEWSWIRE
Bionomics Announces Upcoming Poster Presentation at the (ASCP) Annual Meeting
30 May 2023 //
GLOBENEWSWIRE
Bionomics completes target enrolment in Phase IIb trial of PTSD therapy
29 Apr 2023 //
PHARMABIZ
Bionomics Announces the Completion in Ph 2b ATTUNE Clinical Trial of BNC210
27 Apr 2023 //
GLOBENEWSWIRE
Bionomics Half-Year Report
23 Feb 2023 //
GLOBENEWSWIRE
Quarterly Activities and Cashflow Report
30 Jan 2023 //
GLOBENEWSWIRE
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210
19 Dec 2022 //
GLOBENEWSWIRE
Bionomics` lead asset fails to reduce public speaking anxiety
19 Dec 2022 //
FIERCEBIOTECH
Bionomics` lead asset fails to reduce public speaking anxiety
19 Dec 2022 //
FIERCEBIOTECH
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and CEO
15 Dec 2022 //
GLOBENEWSWIRE
Bionomics Announces Accepted Abstract and Upcoming Poster at (ACNP) 2022
02 Dec 2022 //
GLOBENEWSWIRE
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering
21 Nov 2022 //
GLOBENEWSWIRE
Bionomics Limited Announces Pricing of Underwritten Offering
16 Nov 2022 //
PRESS RELEASE
Bionomics Limited to Participate in Upcoming November Investor Conferences
02 Nov 2022 //
PRESS RELEASE
Bionomics (BNOX) Stock Falls Over 15%: Details
01 Nov 2022 //
PRESS RELEASE
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
04 Oct 2022 //
GLOBENEWSWIRE
Bionomics to Participate in Upcoming September Investor Conferences
31 Aug 2022 //
GLOBENEWSWIRE
Bionomics reports Full Year Financial Results
25 Aug 2022 //
GLOBENEWSWIRE
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
08 Aug 2022 //
GLOBENEWSWIRE
Bionomics to Participate in William Blair`s Biotech Focus Conference 2022
08 Jul 2022 //
GLOBENEWSWIRE
Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference
27 Jun 2022 //
GLOBENEWSWIRE
Bionomics Investor Webinar
13 Jun 2022 //
GLOBENEWSWIRE
Bionomics Limited to Participate in Upcoming Investor Conferences
16 May 2022 //
GLOBENEWSWIRE
Bionomics` Half-Year Report
23 Feb 2022 //
GLOBENEWSWIRE
Bionomics to Ring Nasdaq Stock Market Closing Bell on Friday January 14, 2022
14 Jan 2022 //
PRNEWSWIRE
Bionomics Announces Full Exercise of Underwriters` Option to Purchase Addn. ADSs
05 Jan 2022 //
PRNEWSWIRE
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 in Social Anxiety Disorder
03 Jan 2022 //
PRNEWSWIRE
Bionomics Announces Pricing of IPO in the United States
16 Dec 2021 //
PRNEWSWIRE
Bionomics Files Registration Statement for Proposed IPO in US
23 Nov 2021 //
PRNEWSWIRE
FDA Clears Bionomics` IND for Evaluation of BNC210 in Phase 2 SAD Study
01 Nov 2021 //
PRNEWSWIRE
Bionomics gets FDA approval for trial of social anxiety disorder treatment
01 Nov 2021 //
CLINICALTRIALSARENA
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment
20 Sep 2021 //
PRNEWSWIRE
Bionomics BNC210 Expansion into Social Anxiety Disorder
10 May 2021 //
PRNEWSWIRE
Bionomics Successfully Completes A$22.9 million Equity Raise
09 Apr 2021 //
PRNASIA
